Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Why Aria Pharmaceuticals is upbeat about two novel IPF treatment candidates 

By Brian Buntz | September 23, 2021

Aria PharmaceuticalsSmall molecule drug developer Aria Pharmaceuticals (Palo Alto, Calif.) recently revealed that two investigational treatments for idiopathic pulmonary fibrosis (IPF), TXR-1002 and TXR-1007, demonstrated promising results in preclinical research.

There are currently only two FDA-approved treatments for IPF on the market — nintedanib (Ofev) from Boehringer Ingelheim and pirfenidone (Esbriet) from Roche. While those introductions marked a turning point in treating IPF, managing the disease remains challenging for many patients.

Both TXR-1002 and TXR-1007 rely on a mechanism of action that is distinct from that of nintedanib or pirfenidone. And Aria reports that preclinical testing indicated that the drugs were well tolerated. “Certainly, you can’t tell if a rat is suffering from nausea or something like that, but at a gross level, the animals did well through the course of the study,” said Mark Eller, senior vice president, R&D at Aria Pharmaceuticals. “We’re optimistic based on the mechanism and the data that we’ve collected so far that we’re onto something.”

[Related: Aria Pharmaceuticals announces positive in vivo data for two idiopathic pulmonary fibrosis candidates]

In general, it can be challenging to develop drugs for idiopathic pulmonary fibrosis, given its unclear etiology.

Mark Eller

Mark Eller

“It’s hard to say that any given animal model is really good for something that’s idiopathic,” Eller acknowledged. But the animal model Aria used is “sort of the gold standard” and “was used for both nintedanib and pirfenidone.”

The model considers both inflammation and fibrosis. TXR-1002 and TXR-1007 fared well in both respects.

The company plans to conduct further testing on the two drug candidates.

The preclinical research indicates that the drug candidates have significant efficacy in reducing lung collagen and the infiltration of neutrophils and lymphocytes in the lung, which are markers for inflammation.

“Usually, it’s the inflammation that comes first, and then the fibrosis follows that,” Eller said. Thus, Aria’s model was focused on quantifying lung damage associated with fibrosis. In that respect, the company had “statistically significant results — in fact, numerically superior to nintedanib for lung collagen, which is a fibrosis marker.”

Eller said that the reductions in neutrophils and lymphocytes were not statistically significant. “That’s probably due to the timing,” he said. Because inflammation precedes fibrosis, the company could potentially measure both variables at various times to get a clearer picture of how the investigational drugs impact both factors.

The prevalence of IPF appears to have risen in recent decades, according to a 2018 paper published in Medical Sciences. In addition, the ongoing pandemic and factors such as rampant wildfires could heighten the need for new IPF treatments. Researchers have also identified that certain occupations such as firefighting may elevate the risk for interstitial lung diseases, including IPF. “It is an important area for continued research on the part of the pharmaceutical industry,” Eller concluded.


Filed Under: Pulmonology
Tagged With: Aria Pharmaceuticals, Idiopathic pulmonary fibrosis, lymphocytes, neutrophils, nintedanib, pirfenidone, pulmonary fibrosis, TXR-1002, TXR-1007
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Dupixent bests Xolair in first head-to-head respiratory trial: 4 takeaways
Insilico Medicine
Insilico’s AI-designed rentosertib shows promise in first phase 2a trial results
GSK
GSK’s Nucala wins U.S. nod as first IL-5 biologic for COPD
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE